NCT01508455
已完成
2 期
A Phase II/III, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age
Hospira, now a wholly owned subsidiary of Pfizer0 个研究点目标入组 6 人2012年3月
适应症Anesthesia
概览
- 阶段
- 2 期
- 干预措施
- Dexmedetomidine
- 疾病 / 适应症
- Anesthesia
- 发起方
- Hospira, now a wholly owned subsidiary of Pfizer
- 入组人数
- 6
- 主要终点
- Percent of Subjects Requiring Rescue Midazolam for Sedation
- 状态
- 已完成
- 最后更新
- 8年前
概览
简要总结
The primary objective of this study is to characterize the safety, and efficacy of Dexmedetomidine (DEX) administered as an intravenous (IV) loading dose followed by a continuous IV infusion in preterm subjects, ages ≥ 28 weeks through < 36 weeks gestational age.
研究者
入排标准
入选标准
- •Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require at least 6 hours of continuous IV sedation.
- •Age: subjects must fit the following age range at screening:
- •Preterm subjects ≥28 weeks through \<36 weeks, gestational age;
- •Note: Gestational age (in weeks) will be calculated as follows: the time elapsed between the first day of the last menstrual period and the day of enrollment.
- •Weight: subject's weight at the time of enrollment must be \>1000 g.
- •Subject's parent(s) or legal guardian(s) has/have voluntarily signed and dated the informed consent document approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
排除标准
- •Neonate subjects with neurological conditions that prohibit an evaluation of sedation such as:
- •Diminished consciousness from increased intracranial pressure.
- •The presence of catastrophic brain injury or other severe mental disorders that would make responses to sedatives unpredictable and/or measurement of the N-PASS unreliable.
- •Subjects with immobility from neuromuscular disease or continuous infusion of neuromuscular blocking (NMB) agents.
- •Subjects with second degree or third degree heart block unless subject has a pacemaker or pacing wires are in situ.
- •Note: If subject's status-post Cardio Pulmonary Bypass (CPB) was managed without pacing wires in situ, the subject must not be suspected to be in second degree or third degree heart block at the time of DEX administration.
- •HR \< 120 bpm prior to the initiation of DEX.
- •Exposure to any investigational drug within 30 days prior to DEX administration.
- •Previous exposure to DEX as part of an investigational study.
- •In subjects that are ex-utero for less than 72 hours, a maternal history of poly-substance drug abuse, based upon the Investigator's clinical judgment.
研究组 & 干预措施
Dexmedetomidine
Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
干预措施: Dexmedetomidine
Dexmedetomidine
Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
干预措施: Midazolam
Dexmedetomidine
Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
干预措施: Fentanyl
Dexmedetomidine
Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
干预措施: Morphine
结局指标
主要结局
Percent of Subjects Requiring Rescue Midazolam for Sedation
时间窗: During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).
次要结局
- Incidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion(During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).)
- Amount of Rescue Medication (Midazolam) for Sedation During Dexmedetomidine Infusion(During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).)
- Amount of Rescue Medication for Analgesia During DEX Infusion(During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).)
- Time Spent With a Total N-PASS Score >3 During DEX Infusion(Predose, loading dose (LD) 5 & 10mins/if LD is 20mins (5, 10, 15 & 20mins); maintenance infusion: 0 min, every 15mins (1st hr); every 30mins (2hrs), then hourly; within 5mins of DEX discontinuation; 5mins pre and post rescue medication)
- Time to Successful Extubation(From the start of study drug infusion to the study completion/withdrawal (Approximately 48 hours))
相似试验
已完成
3 期
A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)AnesthesiaSurgical Procedures, ElectiveNCT00398827Hospira, now a wholly owned subsidiary of Pfizer326
招募中
1 期
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsAdvanced Unresectable or Metastatic Breast CancerNCT06679036Shandong Suncadia Medicine Co., Ltd.300
终止
不适用
Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation ProceduresTachyarrhythmiaNCT03451227University Health Network, Toronto6
Unknown
2 期
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of AdultsPreoperative SedationNCT04383418Jiangsu HengRui Medicine Co., Ltd.201
已完成
3 期
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of ChildrenPreoperative Sedation of ChildrenNCT05111431Shanghai Hengrui Pharmaceutical Co., Ltd.159